Back to Directory
Last Updated: 09/06/2026
Biosceptre
Cambridge
Founded 2003
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform.
The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches.
The pipeline includes a CAR-T system, a monoclonal antibody programme, a peptide vaccine in Phase I trials, and a topical antibody formulation for basal cell carcinoma.
Diagnostic and veterinary therapeutic applications are also in development.